Compare TYGO & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYGO | HELP |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.1M | 279.9M |
| IPO Year | 2021 | N/A |
| Metric | TYGO | HELP |
|---|---|---|
| Price | $4.80 | $5.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $51.50 |
| AVG Volume (30 Days) | 537.1K | ★ 1.5M |
| Earning Date | 05-05-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.12 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $103,536,000.00 | N/A |
| Revenue This Year | $30.78 | N/A |
| Revenue Next Year | $21.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 91.68 | N/A |
| 52 Week Low | $0.81 | $4.29 |
| 52 Week High | $5.33 | $8.55 |
| Indicator | TYGO | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 59.79 | 46.93 |
| Support Level | $3.24 | $4.55 |
| Resistance Level | N/A | $8.55 |
| Average True Range (ATR) | 0.46 | 0.46 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 68.85 | 22.72 |
Tigo Energy Inc provides solar and energy storage solutions, including module level power electronics (MLPE) designed to maximize the energy output of individual solar modules, delivering more energy, active management, and enhanced safety for utility, commercial, and residential solar arrays. By combining its MLPE and solar optimizer technology with intelligent, cloud-based software capabilities, the Company enables developed energy monitoring, system diagnostics, and real-time control. Geographically the company generates revenue from EMEA, Americas, and APAC.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.